Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples